These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39288199)

  • 1. Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023.
    Mahasing C; Suphanchaimat R; Teekasap P; Nittayasoot N; Wongsanuphat S; Thammawijaya P
    PLoS One; 2024; 19(9):e0310427. PubMed ID: 39288199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific.
    Bilgin GM; Munira SL; Lokuge K; Glass K
    PLoS One; 2024; 19(9):e0294091. PubMed ID: 39348348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.
    Harrison C; Butfield R; Yarnoff B; Yang J
    Expert Rev Vaccines; 2024; 23(1):730-739. PubMed ID: 39072472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance.
    Sirison K; Nittayasoot N; Techasuwanna R; Cetthakrikul N; Suphanchaimat R
    Trop Med Infect Dis; 2023 Jan; 8(2):. PubMed ID: 36828507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritization of the Target Population for Coronavirus Disease 2019 (COVID-19) Vaccination Program in Thailand.
    Suphanchaimat R; Tuangratananon T; Rajatanavin N; Phaiyarom M; Jaruwanno W; Uansri S
    Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
    Painter C; Isaranuwatchai W; Prawjaeng J; Wee HL; Chua BWB; Huynh VA; Lou J; Goh FT; Luangasanatip N; Pan-Ngum W; Yi W; Clapham H; Teerawattananon Y
    Appl Health Econ Health Policy; 2021 Jul; 19(4):463-472. PubMed ID: 34235643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Li R; Liu H; Fairley CK; Ong JJ; Guo Y; Lu P; Zou Z; Xie L; Zhuang G; Li Y; Shen M; Zhang L
    Vaccine; 2023 Apr; 41(15):2439-2446. PubMed ID: 36781332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.
    Nagano M; Kamei K; Matsuda H; Takahashi C; Yang J; Wada K; Yonemoto N
    Expert Rev Vaccines; 2024; 23(1):349-361. PubMed ID: 38411109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Edoka I; Silal S; Jamieson L; Meyer-Rath G
    Vaccine; 2024 Aug; 42(20):125988. PubMed ID: 38824084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
    Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
    BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis.
    Chang E; Li H; Zheng W; Zhou L; Jia Y; Gu W; Cao Y; Zhu X; Xu J; Liu B; You M; Liu K; Wang M; Huang W
    Appl Health Econ Health Policy; 2024 Jul; 22(4):457-470. PubMed ID: 38598091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
    Wells CR; Pandey A; Moghadas SM; Fitzpatrick MC; Singer BH; Galvani AP
    Ann Intern Med; 2024 May; 177(5):609-617. PubMed ID: 38527289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.
    Deng J; Ma Y; Liu Q; Du M; Liu M; Liu J
    Int J Environ Res Public Health; 2022 Aug; 19(17):. PubMed ID: 36078466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    van Ewijk CE; Hazelhorst EI; Hahné SJM; Knol MJ
    Vaccine; 2022 Nov; 40(46):6664-6669. PubMed ID: 36216647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Korves C; Izurieta HS; Smith J; Zwain GM; Powell EI; Balajee A; Ryder KM; Young-Xu Y
    Vaccine; 2022 Aug; 40(33):4742-4747. PubMed ID: 35773122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
    Ren J; Huang Z; Tian J; Li Z; Shen S; Yan H; Wang N; Hu J; Ma X; Ma Z; Liu J; Lu Y; Sun X
    Vaccine; 2024 Aug; 42(21):126162. PubMed ID: 39069462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.